Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study

IntroductionReal-world, country-specific studies of dual antiplatelet therapy (DAPT) duration among survivors of acute coronary syndrome (ACS) are important for improving long-term prognosis. AimsTo investigate DAPT duration after hospital discharge for ACS in Spain. ResultsData from patients enroll...

Descripción completa

Detalles Bibliográficos
Autores: Bardaji, A, Leal, M, Arrarte, V, Garcia-Moll, X, de Isla, LP, Bueno, H
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p6557
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6557
http://hdl.handle.net/20.500.12105/11262
Access Level:acceso abierto
Palabra clave:Acute coronary syndrome
ADP Receptor antagonists
Antiplatelet agents
Coronary artery disease
Myocardial infarction
Secondary prevention
id ES_c8a3910896c2db5f52a8d12294ef6864
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p6557
network_acronym_str ES
network_name_str España
repository_id_str
spelling Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR studyBardaji, ALeal, MArrarte, VGarcia-Moll, Xde Isla, LPBueno, HAcute coronary syndromeADP Receptor antagonistsAntiplatelet agentsCoronary artery diseaseMyocardial infarctionSecondary preventionIntroductionReal-world, country-specific studies of dual antiplatelet therapy (DAPT) duration among survivors of acute coronary syndrome (ACS) are important for improving long-term prognosis. AimsTo investigate DAPT duration after hospital discharge for ACS in Spain. ResultsData from patients enrolled in the Spanish cohort of the EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study (NCT01171404) were analyzed for changes to antithrombotic medication up to 2years postdischarge according to index event diagnosis and patient characteristics. Deaths, coronary events, and bleeding events were analyzed over the same period. Overall, a high proportion of patients remained on DAPT at 2years (53.1%). Among patients who experienced any on-treatment bleeding event, almost two-thirds remained on DAPT at the end of follow-up. Patients >65years, diabetic, or those that were medically managed were more likely to continue with DAPT until 2years following discharge. At 2years, the incidence of bleeding events requiring hospitalization was low compared with the incidence of coronary events (1.4% vs 6.6%). There was a numerical reduction in coronary events, but no increase in bleeding events, with DAPT continuation compared with single antiplatelet therapy. ConclusionsMore than half of patients in this unselected cohort study remained on DAPT at 2 years following discharge for ACS. Continuation with DAPT was greater among patients with additional cardiovascular risk factors, which suggests that treating physicians in Spain prioritizes ischemic risk reduction over bleeding risk in patients with ACS, according to patient's risk profile.WILEY2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6557http://hdl.handle.net/20.500.12105/11262Cardiovascular TherapeuticsISSN: 17555914ISSNe: 17555922reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p65572026-06-14T12:41:47Z
dc.title.none.fl_str_mv Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study
title Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study
spellingShingle Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study
Bardaji, A
Acute coronary syndrome
ADP Receptor antagonists
Antiplatelet agents
Coronary artery disease
Myocardial infarction
Secondary prevention
title_short Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study
title_full Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study
title_fullStr Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study
title_full_unstemmed Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study
title_sort Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study
dc.creator.none.fl_str_mv Bardaji, A
Leal, M
Arrarte, V
Garcia-Moll, X
de Isla, LP
Bueno, H
author Bardaji, A
author_facet Bardaji, A
Leal, M
Arrarte, V
Garcia-Moll, X
de Isla, LP
Bueno, H
author_role author
author2 Leal, M
Arrarte, V
Garcia-Moll, X
de Isla, LP
Bueno, H
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Acute coronary syndrome
ADP Receptor antagonists
Antiplatelet agents
Coronary artery disease
Myocardial infarction
Secondary prevention
topic Acute coronary syndrome
ADP Receptor antagonists
Antiplatelet agents
Coronary artery disease
Myocardial infarction
Secondary prevention
description IntroductionReal-world, country-specific studies of dual antiplatelet therapy (DAPT) duration among survivors of acute coronary syndrome (ACS) are important for improving long-term prognosis. AimsTo investigate DAPT duration after hospital discharge for ACS in Spain. ResultsData from patients enrolled in the Spanish cohort of the EPICOR (long-tErm follow-up of antithrombotic management Patterns In acute CORonary syndrome patients) study (NCT01171404) were analyzed for changes to antithrombotic medication up to 2years postdischarge according to index event diagnosis and patient characteristics. Deaths, coronary events, and bleeding events were analyzed over the same period. Overall, a high proportion of patients remained on DAPT at 2years (53.1%). Among patients who experienced any on-treatment bleeding event, almost two-thirds remained on DAPT at the end of follow-up. Patients >65years, diabetic, or those that were medically managed were more likely to continue with DAPT until 2years following discharge. At 2years, the incidence of bleeding events requiring hospitalization was low compared with the incidence of coronary events (1.4% vs 6.6%). There was a numerical reduction in coronary events, but no increase in bleeding events, with DAPT continuation compared with single antiplatelet therapy. ConclusionsMore than half of patients in this unselected cohort study remained on DAPT at 2 years following discharge for ACS. Continuation with DAPT was greater among patients with additional cardiovascular risk factors, which suggests that treating physicians in Spain prioritizes ischemic risk reduction over bleeding risk in patients with ACS, according to patient's risk profile.
publishDate 2017
dc.date.none.fl_str_mv 2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6557
http://hdl.handle.net/20.500.12105/11262
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6557
http://hdl.handle.net/20.500.12105/11262
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv Cardiovascular Therapeutics
ISSN: 17555914
ISSNe: 17555922
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419303075315712
score 15,811543

Similares en LA Referencia